Moderna (MRNA) Cash from Operations Growth (3y) (2021 - 2026)

Moderna (MRNA) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Moderna 21.94 Bn 16.73 Bn -566.00 Mn 19.88%

Historic Data

Download Data
DateValue
Mar 31, 2026 19.88%
Dec 31, 2025 -17.60%
Sep 30, 2025 -75.02%
Jun 30, 2025 -71.26%
Mar 31, 2025 -33.43%
Dec 31, 2024 -37.07%
Sep 30, 2024 -35.32%
Jun 30, 2024 -32.26%
Mar 31, 2024 -32.63%
Dec 31, 2023 -21.05%
Sep 30, 2023 -55.94%
Jun 30, 2023 -236.57%
Mar 31, 2023 -126.09%
Dec 31, 2022 165.80%
Sep 30, 2022 63.28%
Jun 30, 2022 68.68%
Mar 31, 2022 176.56%
Dec 31, 2021 237.27%
Sep 30, 2021 249.91%
Jun 30, 2021 341.76%